SCHEMBL29422699

SCHEMBL29422699

CCOC(=O)c1cnn2ccc(N[C@H](C)c3cc(F)cc4c3O[C@@](C)(CNC(=O)OC(C)(C)C)C4)nc12

nearest known ligand 0.38

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 20/20 0.38
▸ NTRK3 Q16288 9/20 0.38
▸ NTRK2 Q16620 8/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22688782 1.00 NTRK1 (0.38) NTRK1NTRK3NTRK2
SCHEMBL22688784 1.00 NTRK1 (0.38) NTRK1NTRK3NTRK2
SCHEMBL22688844 1.00 NTRK1 (0.38) NTRK1NTRK3NTRK2
SCHEMBL22695121 1.00 NTRK1 (0.38) NTRK1NTRK3NTRK2
SCHEMBL22688845 1.00 NTRK1 (0.38) NTRK1NTRK3NTRK2
SCHEMBL29422764 0.94 NTRK1 (0.38) NTRK1NTRK3NTRK2
SCHEMBL29422547 0.94 NTRK1 (0.38) NTRK1NTRK3NTRK2
SCHEMBL22695326 0.94 NTRK1 (0.38) NTRK1NTRK3NTRK2
SCHEMBL22688842 0.93 NTRK1 (0.40) NTRK1NTRK3NTRK2
SCHEMBL22688694 0.93 NTRK1 (0.40) NTRK1NTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3974434-B1 MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF ZHEJIANG HISUN PHARM CO LTD (CN) 2025-11-19 — — EP disclosed
US-12410191-B2 Macrolide derivatives, preparation method and application thereof ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2025-09-09 — — US disclosed
US-20220235070-A1 MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF SHANGHAI ARYL PHARMTECH CO., LTD. (CN) 2022-07-28 — — US disclosed
EP-3974434-A1 MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) 2022-03-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235070-A1 MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF ROS1, IRAK1, IRAK2 NTRK1 51/4885NTRK3 71/4885NTRK2 336/4885
US-12410191-B2 Macrolide derivatives, preparation method and application thereof ROS1, IRAK1, IRAK2 NTRK1 51/4885NTRK3 71/4885NTRK2 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback